Table 1 Baseline characteristics of patients recieving TDF or ETV therapy after LT for HBV-related HCC in the entire cohort and PSM cohort
Characteristics | Entire cohort (n = 316) | Propensity socre matched cohort (n = 106) | ||||
|---|---|---|---|---|---|---|
ETV (n = 272) | TDF (n = 44) | P value | ETV (n = 68) | TDF (n = 38) | P value | |
Demographic characteristics | Â | Â | Â | Â | Â | Â |
Male gender, n (%) | 254 (93.4) | 41 (93.2) | 1.000 | 63 (92.6) | 35 (92.1) | 1.000 |
Age (median [IQR]) | 52 [46, 59] | 50 [44, 54] | 0.055 | 52 [46, 56] | 50 [44, 55] | 0.410 |
LRT before LT, n (%) | 127 (46.7) | 22 (50) | 0.806 | 31 (45.6) | 20 (52.6) | 0.622 |
Tumor characteristics | Â | Â | Â | Â | Â | Â |
Maximum tumor size (median (IQR)), cm | 3.8 (2.1, 6.0) | 3.5 (2.5, 5.1) | 0.449 | 35.0 [17.8, 56.2] | 34.5 [25.0, 50.0] | 0.739 |
Number of lesion ≥ 3, n (%) | 139 (51.1) | 21 (47.1) | 0.800 | 32 (47.1) | 19 (50.0) | 0.930 |
MAV, n (%) | 90 (33.1) | 10 (22.7) | 0.232 | 16 (23.5) | 10 (26.3) | 0.933 |
MIV, n (%) | 179 (65.8) | 17 (38.6) | 0.001 | 34 (50.0) | 15 (39.5) | 0.401 |
Macrovascular tumor thrombus, n (%) | 80 (29.4) | 7 (13.6) | 0.046 | 14 (20.6) | 6 (15.8) | 0.729 |
Differentiation of tumor, n (%) | Â | Â | 0.791 | Â | Â | 0.639 |
  None survival tumor | 23 (8.5) | 2 (4.5) |  | 5 (7.4) | 2 (5.3) |  |
  Well | 22 (8.1) | 3 (6.8) |  | 4 (5.9) | 3 (7.9) |  |
  Moderate | 191 (70.2) | 32 (72.7) |  | 46 (67.6) | 29 (76.3) |  |
  Poor | 36 (13.2) | 7 (15.9) |  | 13 (19.1) | 4 (10.5) |  |
Satellite nodule, n (%) | 62 (22.8) | 7 (15.9) | 0.407 | 13 (19.1) | 7 (18.4) | 1.000 |
Beyond MC, n (%) | 83 (30.5) | 14 (31.8) | 1.000 | 25 (36.8) | 11 (28.9) | 0.548 |
Laboratory findings before LT | Â | Â | Â | Â | Â | Â |
AFP (median [IQR]), ng/ml | 32.8 [5.9, 617.7] | 36.1 [6.5, 270.8] | 0.820 | 32.4 [6.2, 544.5] | 22.8 [7.4, 183.2] | 0.849 |
PT (median [IQR]), sec | 14.9 [13.8, 17.2] | 14.8 [13.8, 19.0] | 0.602 | 15.4 [13.7, 17.9] | 15.3 [13.9, 19.6] | 0.843 |
FIB (median [IQR]), g/L | 2.7 [2.0, 3.7] | 2.8 [1.7, 3.7] | 0.805 | 2.5 [1.9, 3.8] | 2.7 [1.7, 3.5] | 0.963 |
INR (median [IQR]) | 1.2 [1.0, 1.4] | 1.2 [1.1, 1.7] | 0.353 | 1.2 [1.0, 1.5] | 1.2 [1.1, 1.6] | 0.624 |
TB (median [IQR]), umol/L | 24.0 [13.3, 42.2] | 23.1 [12.4, 84.4] | 0.787 | 21.4 [13.5, 49.0] | 21.7 [12.8, 63.0] | 0.715 |
ALB (median [IQR]), g/L | 36.3 [32.3, 40.4] | 34.9 [31.4, 38.7] | 0.179 | 35.6 [31.6, 40.5] | 35.9 [32.8, 39.5] | 0.911 |
Cr (median [IQR]), umol/L | 73.0 [63.0, 84.0] | 70.5 [60.0, 88.8] | 0.953 | 77.0 [65.0, 84.2] | 70.5 [60.5, 85.8] | 0.420 |
MELD score (median [IQR]) | 9.9 [7.6, 14.1] | 11.0 [7.5, 20.5] | 0.216 | 11.6 [11.6, 43.6] | 11.6 [11.6, 43.6] | 0.417 |
HBVDNA ≥ 5log10 copy/ml, n (%) | 32 (11.8) | 5 (11.4) | 1.000 | 8 (11.8) | 5 (13.2) | 1.000 |
HBV recurrence after LT | 55 (20.2) | 3 (6.8) | 0.055 | 10 (14.7) | 3 (7.9) | 0.474 |
Other characteristics | Â | Â | Â | Â | Â | Â |
Steatosis of donor liver (median [IQR]),% | 0.0 [0.0, 9.0] | 4.0 [0.0, 19.2] | 0.015 | 4.0 [0.0, 10.0] | 4.5 [0.0, 16.8] | 0.630 |
Valley concentration of FK506 (> 10 ng/ml)or Ciclosporinin (> 300 ng/ml)in 1 month, n (%) | 64 (23.5) | 6 (13.6) | 0.204 | 9 (13.2) | 6 (15.8) | 0.943 |
CIT (median [IQR]) | 360 [340,4 17] | 359.0 [300, 391] | 0.110 | 364 [323, 412] | 355.0 [300, 388] | 0.141 |
Follow up time (median[IQR]), month | 24.0 [13.0, 39.0] | 15.5 [8.0, 29.0] | 0.004 | 26.0 [16.8, 39.8] | 16.0 [9.2, 29.0] | 0.010 |